{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:18:24Z","timestamp":1789676304221,"version":"4.0.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1124\/dmd.105.007237","type":"journal-article","created":{"date-parts":[[2006,1,14]],"date-time":"2006-01-14T01:45:02Z","timestamp":1137203102000},"page":"608-611","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":125,"title":["IN VITRO AND IN VIVO INHIBITORY EFFECT OF STIRIPENTOL ON CLOBAZAM METABOLISM"],"prefix":"10.1016","volume":"34","author":[{"given":"Carole","family":"Giraud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Treluyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Chiron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Pons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.105.007237_bib1","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0387-7604(12)80025-8","article-title":"Monitoring of concentrations of clobazam and norclobazam in serum and saliva of children with epilepsy.","volume":"13","author":"Bardy","year":"1991","journal-title":"Brain Dev"},{"key":"10.1124\/dmd.105.007237_bib2","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1046\/j.0306-5251.2003.01919.x","article-title":"Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human.","volume":"56","author":"Cazali","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.105.007237_bib3","first-page":"1","article-title":"Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes.","volume":"26","author":"Chauret","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.007237_bib4","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(00)03157-3","article-title":"Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial.","volume":"356","author":"Chiron","year":"2000","journal-title":"Lancet"},{"key":"10.1124\/dmd.105.007237_bib5","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/00007691-200212000-00009","article-title":"Evidence of polymorphic CYP2C19 involvement in the human metabolism of N-desmethylclobazam.","volume":"24","author":"Contin","year":"2002","journal-title":"Ther Drug Monit"},{"key":"10.1124\/dmd.105.007237_bib6","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1124\/dmd.32.11.1279","article-title":"In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19.","volume":"32","author":"Giraud","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.007237_bib7","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.braindev.2004.02.010","article-title":"A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam.","volume":"26","author":"Kosaki","year":"2004","journal-title":"Brain Dev"},{"key":"10.1124\/dmd.105.007237_bib8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2133\/dmpk.19.83","article-title":"Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1\/ABCB1.","volume":"19","author":"Ozawa","year":"2004","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.105.007237_bib9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0387-7604(03)00074-3","article-title":"Unusual side-effects due to clobazam: a case report with genetic study of CYP2C19.","volume":"26","author":"Parmeggiani","year":"2004","journal-title":"Brain Dev"},{"key":"10.1124\/dmd.105.007237_bib10","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1528-1157.1999.tb02048.x","article-title":"Stiripentol: efficacy and tolerability in children with epilepsy.","volume":"40","author":"Perez","year":"1999","journal-title":"Epilepsia"},{"key":"10.1124\/dmd.105.007237_bib11","series-title":"Antiepileptic Drugs","first-page":"763","article-title":"Benzodiazepines: clobazam","author":"Shorvon","year":"1995"},{"key":"10.1124\/dmd.105.007237_bib12","first-page":"1120","article-title":"Long-term efficacy and tolerance of stiripentol in severe myoclonic epilepsy of infancy (Dravet\u2019s syndrome)","volume":"9","author":"Thanh","year":"2002","journal-title":"Arch Pediatr"},{"key":"10.1124\/dmd.105.007237_bib13","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0009-9236(97)90044-8","article-title":"Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants.","volume":"62","author":"Tran","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.105.007237_bib14","doi-asserted-by":"crossref","first-page":"41S","DOI":"10.1111\/j.1365-2125.1979.tb04664.x","article-title":"Kinetics and metabolism of clobazam in animals and man.","volume":"7","author":"Volz","year":"1979","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.105.007237_bib15","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF01117450","article-title":"Application of Akaike\u2019s information criterion (AIC) in the evaluation of linear pharmacokinetic equations.","volume":"6","author":"Yamaoka","year":"1978","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1124\/dmd.105.007237_bib16","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1067\/mcp.2001.114231","article-title":"Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19.","volume":"69","author":"Yu","year":"2001","journal-title":"Clin Pharmacol Ther"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624034548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624034548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.105.007237","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T17:42:56Z","timestamp":1739900576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624034548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["S0090955624034548"],"URL":"https:\/\/doi.org\/10.1124\/dmd.105.007237","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2006,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IN VITRO AND IN VIVO INHIBITORY EFFECT OF STIRIPENTOL ON CLOBAZAM METABOLISM","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.105.007237","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2006 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}